Literature DB >> 7745111

c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus.

R H Hardwick1, N A Shepherd, M Moorghen, P V Newcomb, D Alderson.   

Abstract

AIMS--To investigate overexpression of the oncoprotein c-erbB-2 in the dysplasia/carcinoma sequence of Barrett's columnar-lined oesophagus (CLO). METHODS--Immunohistochemical staining was performed using the monoclonal antibody NCL-CB-11 on formalin fixed tissue from 31 cases of Barrett's carcinoma, 20 cases of cancer associated dysplastic CLO, seven cases of dysplastic CLO without cancer, and 20 cases of non-dysplastic CLO. Membranous staining was regarded as positive for c-erbB-2 overexpression; cytoplasmic staining was recorded separately as its significance is uncertain. RESULTS--Membranous c-erbB-2 overexpression was observed in eight of 31 (26%) carcinomas and in none of the cases of dysplastic CLO. Variable cytoplasmic staining was seen in four of 31 (13%) tumours and seven of 27 (26%) cases of dysplastic CLO. No staining was observed in non-dysplastic CLO. CONCLUSIONS--C-erbB-2 overexpression is a relatively late event in the development of some Barrett's carcinomas and is unlikely to be involved in the early stages of neoplastic transformation of CLO.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7745111      PMCID: PMC502378          DOI: 10.1136/jcp.48.2.129

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  32 in total

1.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

2.  Endoscopic surveillance for patients with Barrett esophagus: does the cancer risk justify the practice?

Authors:  S J Spechler
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

3.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

Authors:  C I Bargmann; M C Hung; R A Weinberg
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

4.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

5.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

6.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

7.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

8.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications.

Authors:  R H Riddell; H Goldman; D F Ransohoff; H D Appelman; C M Fenoglio; R C Haggitt; C Ahren; P Correa; S R Hamilton; B C Morson
Journal:  Hum Pathol       Date:  1983-11       Impact factor: 3.466

9.  Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction.

Authors:  S R Hamilton; R R Smith; J L Cameron
Journal:  Hum Pathol       Date:  1988-08       Impact factor: 3.466

10.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

View more
  13 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

Review 2.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

3.  Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.

Authors:  Taher Abu Hejleh; Barry R Deyoung; Eric Engelman; Jeremy M Deutsch; Bridget Zimmerman; Thorvardur R Halfdanarson; Daniel J Berg; Kalpaj R Parekh; William R Lynch; Mark D Iannettoni; Sudershan Bhatia; Gerald Clamon
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

4.  Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.

Authors:  Jun Hong; Ahmed Katsha; Pengcheng Lu; Yu Shyr; Abbes Belkhiri; Wael El-Rifai
Journal:  Cancer Res       Date:  2012-06-28       Impact factor: 12.701

5.  Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

Authors:  Matthew D Galsky; Daniel D Von Hoff; Marcus Neubauer; Thomas Anderson; Mark Fleming; Yasir Nagarwala; Janine M Mahoney; Dawn Midwinter; Linda Vocila; Tal Z Zaks
Journal:  Invest New Drugs       Date:  2010-09-22       Impact factor: 3.850

6.  Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.

Authors:  Matthew D Galsky; Tal Zaks; Habib Hassani; Linda Vocila; Guru Sonpavde; Thomas E Hutson; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2009-03-06       Impact factor: 3.850

7.  HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.

Authors:  Ashwini Gowryshankar; Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-02

Review 8.  In vivo cancer biomarkers of esophageal neoplasia.

Authors:  Shaoying Lu; Thomas D Wang
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

9.  Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Authors:  Tadayuki Akagi; Tetsuo Ito; Motohiro Kato; Zhe Jin; Yulan Cheng; Takatsugu Kan; Go Yamamoto; Alexandru Olaru; Norihiko Kawamata; Jessica Boult; Harmik J Soukiasian; Carl W Miller; Seishi Ogawa; Stephen J Meltzer; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

10.  Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma.

Authors:  Takehiro Tanaka; Atsushi Fujimura; Koichi Ichimura; Hiroyuki Yanai; Yasuharu Sato; Katsuyohi Takata; Hiroyuki Okada; Seiji Kawano; Shunsuke Tanabe; Tadashi Yoshino
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.